Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in ... 7thSpace Interactive (press release) The incidence of renal cell cancer (RCC) has been increasing for the past decade, and the 5-year survival for patients with metastatic RCC (mRCC) is rather low. Everolimus (RAD001), a new inhibitor for mammalian target of rapamycin (mTOR), is generally ... |
